Glenmark Pharmaceuticals Ltd

GLENMARK14 Jun 2024
Pharmaceuticals
+12.30 (+1.00%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Glenmark Pharma.
Glenmark Pharmaceuticals Ltd
Pharmaceuticals
GLENMARK14 Jun 2024
+12.30 (+1.00%)
1D
1M
6M
1Y
5Y
All

Glenmark Pharma. - Share Price & Details

Lowest Today
1221.05
Highest Today
1240.75
Today’s Open
1226.15
Prev. Close
1224.85
52 Week High
1240.75
52 Week Low
621.8
Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
94.08%
Upper Circuit
Lower Circuit
P/E TTM
24.48
P/B Ratio
1.52
Traded Value(Cr)
0.00
EPS TTM
50.49
Book value
Dividend
0.20%

Price Performance

3.60 %
1 Wk
22.34 %
1 M
31.96 %
3 M
94.08 %
1 Y
44.59 %
YTD

Traded Volume Movement

Technical Details

Support 3
1206
Support 2
1214
Support 1
1226
Pivot Point :
1233
Resistance 1
1245
Resistance 2
1253
Resistance 3
1265

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Glenmark Pharmaceuticals Ltd
₹1,237.15(+12.30/1.00%)
1,237.15+12.3034,910.9194.0824.481.52
Lupin Ltd
₹1,604.10(-1.35/-0.08%)
1,604.10-1.3573,106.8795.9231.423.55
J B Chemicals & Pharmaceuticals Ltd
₹1,854.30(-31.05/-1.65%)
1,854.30-31.0528,781.1670.3552.969.97
Ipca Laboratories Ltd
₹1,181.35(-18.45/-1.54%)
1,181.35-18.4529,971.3564.8048.674.73
Sanofi India Ltd
₹6,838.70(+325.65/5.00%)
6,838.70+325.6515,749.53-0.8427.7515.51
408.95+20.302,400.76-8.8717.721.49

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 34882.69 crores. It has reported a sales of Rs. 2077.13 crores and a net profit of Rs. 4613.7 crores for the quarter ended December 2018. The company management includes Glenn Saldanha, Glenn Saldanha,Cheryl Pinto,V S Mani,B E Saldanha,Rajesh Desai.,Devendra Raj Mehta,Bernard Munos,Brian W Tempest,Sridhar Gorthi,Sona Saira Ramasastry,Dipankar Bhattacharjee,V R Iyer (Glenmark Pharmaceuticals Ltd) among others.
Chairman
Glenn Saldanha
Registered office
B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road,Mumbai,Maharashtra,400026
FAX :91-22-40189986
Background
Incorporation Year1977
Face Value₹1
Market Lot1

Latest News

Will Nifty touch 24,000 this week? Top 5 factors at play
The Nifty index remains within a narrow range of 23,200-23,500, with a potential breakout above 23,600 leading to a rally up to 24,000. Key factors influencing the market this week include ⏩Global markets, ⏩Macro cues, ⏩FII flow, ⏩Govt &⏩Technicals. Meanwhile, FII selling has reduced, & retail investors are eager to buy every dip, but FPIs may turn sellers again if the market rallies further.
16 Jun 2024 | 11:55 AM
Godawari Power to buy back ₹301 crore shares at ₹1,400 each, board approves
Godawari Power and Ispat's board approved a share buyback of up to 21.5 lakh equity shares at ₹1,400 per share, amounting to ₹301 crore, representing 1.64% of the company's total paid-up equity share capital. This is the company's second buyback, following a ₹250 crore buyback last year. The move aims to return cash to investors in a tax-efficient manner.
16 Jun 2024 | 02:26 PM
Anand Rathi expert recommends three shares to buy on June 18
Indian benchmark equity indices Sensex and Nifty 50 closed positively on Friday. By keeping this in mind Anand Rathi's stock picks for June 18 are:
📌Birla Corporation Ltd: Buy at ₹1560-1580 | Target Price: ₹1750 | Stop Loss: ₹1400.
📌HCL Tech: Buy at ₹1445 | Target Price: ₹1550 | Stop Loss: ₹1390.
📌GMM Pfaudler Ltd: Buy at ₹1355 | Target Price: ₹1420 | Stop Loss: ₹1300.
16 Jun 2024 | 01:40 PM
Emkay Global raises Dabur's target price to Rs 700!
Emkay Global raised Dabur India's TP to Rs 700, citing optimism about consumption revival and confidence in the company's execution. The firm expects Dabur to benefit from steady distribution expansion, innovation, & liquidity for acquisitions, making it their top consumption pick. The stock partially factored in potential demand recovery, but Emkay sees Dabur for any consumption revival.
16 Jun 2024 | 12:09 PM
Will Nifty touch 24,000 this week? Top 5 factors at play
The Nifty index remains within a narrow range of 23,200-23,500, with a potential breakout above 23,600 leading to a rally up to 24,000. Key factors influencing the market this week include ⏩Global markets, ⏩Macro cues, ⏩FII flow, ⏩Govt &⏩Technicals. Meanwhile, FII selling has reduced, & retail investors are eager to buy every dip, but FPIs may turn sellers again if the market rallies further.
16 Jun 2024 | 11:55 AM

How to buy Glenmark Pharma. shares on nse?

To buy Glenmark Pharma. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Glenmark Pharma. share price today?

The Glenmark Pharma. shares price on nse is Rs.1237.15 today.

What is the market cap of Glenmark Pharma. shares on NSE ?

The company has a market capitalization of Rs.34910.91Cr

What is the PE & PB ratio of Glenmark Pharma. shares ?

PE is 24.48 and PB is 1.52

What is the 52 Week High and Low of Glenmark Pharma. shares?

Glenmark Pharma. stock price high: Rs.1240.75 Glenmark Pharma. stock price low: Rs.621.8

How has the GLENMARK share price performed in the past year?

In April 2022, the huge pharmaceutical GLENMARK’s share price was in the region of Rs. 478. By June, it had dipped to the late 300 levels and never significantly went up till November. Highs were felt in December, and February 2023, and now the stock is at the 448 level. 

Does GLENMARK pay dividends to its shareholders?

GLENMARK has a consistent track record of paying dividends to its loyal shareholders. In the recent past, the company has paid only final dividends, but interim dividends have been paid in the past as well. 

What is the dividend yield of GLENMARK?

The dividend yield of GLENMARK is 0.56% (March 2022). 

How does GLENMARK compare to its competitors in terms of share price?

Compared to popular competitors of GLENMARK, like Sun Pharma, Dr Reddy’s Labs, CIPLA, Torrent Pharma, Abbott India and others, the company’s share price is low at the moment (March 2023). Most of these companies have their share prices in the thousands, or late hundreds, whereas GLENMARK seems firmly poised on the mid-hundred mark. 

What is the company's debt-to-equity ratio?

The company’s debt-to-equity ratio is 0.22. 

What is the company's revenue and net income?

The revenue of GLENMARK is Rs. 3,463 crores (Q3 FY 2022-23)  and the net income is Rs. 291 crores (December 2022). 

How long has GLENMARK been in business?

GLENMARK started its foray into the pharmaceutical business with “Candid Cream”, a key dermatological drug, even in use now. The company started its business in 1977, headed by its Founder Emeritus, the late Gracias Saldanha. 

What is the company's history of share price performance?

The share price of GLENMARK has been somewhat stable in the last 4-5 years, not showing much volatility as other pharma stocks have. In 2018, the share was in the region of the 500 mark, peaking at nearly 700 in 2019. Then, with a gradual and slow downward movement, it dipped to the region of 199 in 2020, only to slowly rise to 662 in 2021. Since then, it has been in the range of between 400-500 and is steady now.